These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 38976534)

  • 1. Immune-Mediated Diabetes Mellitus, Diabetic Ketoacidosis, Enteritis, and Thrombotic Thrombocytopenic Purpura Presenting as Adverse Effects of Pembrolizumab Therapy.
    Luong B; Koch G; Trivedi K; Ramachandran K
    Am J Ther; 2024 Jul-Aug 01; 31(4):e474-e475. PubMed ID: 38976534
    [No Abstract]   [Full Text] [Related]  

  • 2. Pembrolizumab-induced thrombotic thrombocytopenic purpura.
    Dickey MS; Raina AJ; Gilbar PJ; Wisniowski BL; Collins JT; Karki B; Nguyen AD
    J Oncol Pharm Pract; 2020 Jul; 26(5):1237-1240. PubMed ID: 31718453
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Diabetic ketoacidosis following immunotherapy for lung cancer.
    Skorpen PK; Margull J
    Tidsskr Nor Laegeforen; 2019 Feb; 139(4):. PubMed ID: 30808100
    [No Abstract]   [Full Text] [Related]  

  • 4. Diabetic ketoacidosis induced by a single dose of pembrolizumab.
    Maamari J; Yeung SJ; Chaftari PS
    Am J Emerg Med; 2019 Feb; 37(2):376.e1-376.e2. PubMed ID: 30361152
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Case reports of acquired thrombotic thrombocytopenic purpura attributed to pembrolizumab.
    Gilbar PJ; Dickey MS
    J Oncol Pharm Pract; 2022 Jul; 28(5):1286-1287. PubMed ID: 35306911
    [No Abstract]   [Full Text] [Related]  

  • 6. Fulminant type 1 diabetes mellitus associated with pembrolizumab.
    Mizab Mellah C; Sánchez Pérez M; Santos Rey MD; Hernández García M
    Endocrinol Diabetes Nutr; 2017 May; 64(5):272-273. PubMed ID: 29056250
    [No Abstract]   [Full Text] [Related]  

  • 7. Pembrolizumab-Induced Diabetes Mellitus Presenting as Diabetic Ketoacidosis in a Patient With Metastatic Colonic Adenocarcinoma.
    Kichloo A; Albosta MS; McMahon S; Movsesian K; Wani F; Jamal SM; Aljadah M; Singh J
    J Investig Med High Impact Case Rep; 2020; 8():2324709620951339. PubMed ID: 32830561
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Thrombotic thrombocytopenic purpura associated with adalimumab (Humira) treatment in Crohn disease.
    Zbaras B; Sam LN; Grimm MC
    Intern Med J; 2013 Feb; 43(2):216-7. PubMed ID: 23402489
    [No Abstract]   [Full Text] [Related]  

  • 9. Atezolizumab-induced autoimmune diabetes mellitus presenting as diabetic ketoacidosis and Takotsubo cardiomyopathy.
    Singhal S; Patel G; Singh RB; Goyal A; Avgush K; Koka J
    BMJ Case Rep; 2022 Jul; 15(7):. PubMed ID: 35793858
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immune Checkpoint Inhibitor-Induced Diabetic Ketoacidosis: A Report of Four Cases and Literature Review.
    Hong AR; Yoon JH; Kim HK; Kang HC
    Front Endocrinol (Lausanne); 2020; 11():14. PubMed ID: 32047478
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Checkpoint inhibitors in the emergency department.
    Bachmeier CA; Morton A
    Emerg Med Australas; 2019 Apr; 31(2):288-289. PubMed ID: 30690867
    [No Abstract]   [Full Text] [Related]  

  • 12. A Severe Case of Diabetic Ketoacidosis and New-Onset Type 1 Diabetes Mellitus Associated with Anti-Glutamic Acid Decarboxylase Antibodies Following Immunotherapy with Pembrolizumab.
    Kedzior SK; Jacknin G; Hudler A; Mueller SW; Kiser TH
    Am J Case Rep; 2021 Jun; 22():e931702. PubMed ID: 34185763
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Programmed Cell Death-1 Inhibitor-Induced Type 1 Diabetes Mellitus.
    Clotman K; Janssens K; Specenier P; Weets I; De Block CEM
    J Clin Endocrinol Metab; 2018 Sep; 103(9):3144-3154. PubMed ID: 29955867
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Severe Immune-Related Enteritis after In Utero Exposure to Pembrolizumab.
    Baarslag MA; Heimovaara JH; Borgers JSW; van Aerde KJ; Koenen HJPM; Smeets RL; Buitelaar PLM; Pluim D; Vos S; Henriet SSV; de Groot JWB; van Grotel M; Rosing H; Beijnen JH; Huitema ADR; Haanen JBAG; Amant F; Gierenz N
    N Engl J Med; 2023 Nov; 389(19):1790-1796. PubMed ID: 37937778
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anti-PD-1 pembrolizumab induced autoimmune diabetes in Chinese patient: A case report.
    Li S; Zhang Y; Sun Z; Hu J; Fang C
    Medicine (Baltimore); 2018 Nov; 97(45):e12907. PubMed ID: 30407284
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A case of pembrolizumab-induced fulminant Type 1 diabetes mellitus in breast cancer.
    Tang Y; Zhao Z; Wang X; Zuo W; Zhang B; Yuan T; Fu Y
    Immunotherapy; 2021 Apr; 13(6):483-489. PubMed ID: 33626915
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Continued administration of pembrolizumab for adenocarcinoma of the lung after the onset of fulminant type 1 diabetes mellitus as an immune-related adverse effect: A case report.
    Edahiro R; Ishijima M; Kurebe H; Nishida K; Uenami T; Kanazu M; Akazawa Y; Yano Y; Mori M
    Thorac Cancer; 2019 May; 10(5):1276-1279. PubMed ID: 30964601
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immune checkpoint inhibitor-induced diabetes mellitus with pembrolizumab.
    Zand Irani A; Almuwais A; Gibbons H
    BMJ Case Rep; 2022 Jan; 15(1):. PubMed ID: 35039353
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Increased risk of immune checkpoint inhibitor-induced type 1 diabetes mellitus with the new approved 6-week scheme of pembrolizumab in patients with melanoma?
    Kähler KC; Kosova K; Bohne AS; Schreiber S; Hauschild A
    Eur J Cancer; 2020 Oct; 138():169-171. PubMed ID: 32890812
    [No Abstract]   [Full Text] [Related]  

  • 20. A case of immune thrombocytopaenia induced by pembrolizumab in a metastatic melanoma patient with a history of immune-mediated pure red cell aplasia.
    Berger M; Amini-Adlé M; Crumbach L; Paubelle E; Dalle S
    Eur J Cancer; 2019 May; 112():94-97. PubMed ID: 30954716
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.